Quick answer
How does NAD+ relate to sirtuin activity, and how should the assay be designed? Sirtuins are NAD+-dependent protein deacylases: each catalytic cycle consumes one NAD+ and releases the deacylated protein, nicotinamide and an ADP-ribose product. NAD+ is therefore a co-substrate, not an activator in the allosteric sense, and the nicotinamide it yields can feed back to inhibit the reaction. A sound assay fixes the NAD+ concentration against the enzyme's apparent affinity, includes no-NAD+ and no-enzyme controls, tracks nicotinamide or product formation, and checks that any small-molecule 'activator' is not an artifact of the detection peptide. NAD+ is supplied for laboratory research use only.
The phrase "NAD+ sirtuin activation" appears in many search queries, and it compresses three different ideas into two words: NAD+ as a substrate, sirtuins as enzymes whose activity depends on it, and small molecules claimed to switch them on. This article separates them. It sets out the reaction, explains what limits the rate in a typical in vitro assay, and lists the controls that make a result interpretable. It is a chemistry and methods article for laboratory research use only. For the structural background see the sibling article on NAD+ structure and biochemical roles, and for catalog context the NAD+ research overview.
The reaction in one paragraph
Sirtuins are the mammalian homologs of the yeast silent information regulator Sir2. The foundational finding was that Sir2 is an NAD-dependent histone deacetylase (Imai et al., 2000), and that members of the Sir2 family catalyze an NAD–nicotinamide exchange reaction that requires an acetylated substrate (Landry et al., 2000). In the overall reaction an acylated lysine on a protein substrate reacts with NAD+; the lysine is deacylated, nicotinamide is released, and the acyl group ends up on an ADP-ribose product. A full review of the chemistry, including the mechanisms proposed for the intermediate steps, is available (Sauve et al., 2006). Two points matter for assay design. First, the reaction consumes NAD+ stoichiometrically, so it is a substrate, not a catalytic cofactor. Second, it releases nicotinamide, which is both a readout and a potential inhibitor.
What 'activation by NAD+' can and cannot mean
In a purified system, increasing NAD+ concentration raises the rate of a sirtuin reaction toward saturation, as it would for any substrate. That is substrate supply, and it is described by the Michaelis constant of the enzyme for NAD+. It is not allosteric activation. In cells the picture is more complicated, because NAD+ is also consumed by other enzymes and because the compartments of the cell hold separate pools. One study in mice reported that the NADase CD38 increases with age and is required for an age-related fall in NAD (Camacho-Pereira et al., 2016), an example of a competing NAD+ consumer that can lower the NAD+ available to sirtuins.
A common source of confusion is the literature on small-molecule "SIRT1 activators". A study that assessed several widely used compounds, including resveratrol, SRT1720, SRT2183 and SRT1460, reported that they are not direct activators of SIRT1, and provided evidence that they interact directly with fluorophore-containing peptide substrates used in the assay (Pacholec et al., 2010). The lesson for a laboratory is about methods: an apparent activation seen with a fluorogenic peptide should be re-tested with an orthogonal readout before it is interpreted as an effect on the enzyme.
Assay formats and what each one reads
| Assay format | What is measured | Strength | Main caution |
|---|---|---|---|
| Fluorogenic peptide substrate | Fluorescence after deacylation and a developer step | High throughput, simple plate readout | Fluorophore-bearing substrates can interact with test compounds (Pacholec et al., 2010) |
| HPLC of unlabeled peptide | Separation of acylated from deacylated peptide | No label; direct product detection | Lower throughput; needs a method for each peptide |
| Nicotinamide release | Free nicotinamide by HPLC or coupled enzyme | Counts turnovers of any substrate | Background from NAD+ hydrolysis in the stock |
| LC-MS of NAD+ and metabolites | NAD+, nicotinamide and related species together | Specific; useful in cell extracts (Trammell and Brenner, 2013) | Needs instrument access and internal standards |
| Cell-based acetylation readout | Acetylation of a known substrate by immunoblot | Reports a cellular outcome | Many NAD-dependent and independent inputs |
Quantitative NAD+ measurement by reverse-phase HPLC has been described for cells and tissues (Yoshino and Imai, 2013), and the same type of method can be used to verify the NAD+ stock before an enzyme experiment.
Controls that make a result readable
A short list covers most interpretation problems.
- No-NAD+ control. The enzyme and substrate without NAD+. Any signal here is not NAD+-dependent and sets the floor.
- No-enzyme control. Substrate and NAD+ without enzyme. This reveals non-enzymatic hydrolysis or signal from the stock itself.
- Nicotinamide spike. Adding nicotinamide at a chosen concentration tests the feedback inhibition that was proposed for yeast Sir2 and human SIRT1 (Bitterman et al., 2002) and shows how much accumulated product the assay tolerates.
- NAD+ titration. Several concentrations bracketing the expected apparent affinity, so that the choice of working concentration is documented rather than assumed.
- Time course. At least three time points inside the linear range, because consumption of NAD+ and accumulation of nicotinamide bend the curve at later times.
- Stock verification. An HPLC check of the NAD+ stock against a fresh standard from the same lot, recorded with the experiment.
| Control | If signal is high | Likely meaning |
|---|---|---|
| No NAD+ | Signal present without cofactor | Non-sirtuin deacylation, or background in the readout |
| No enzyme | Signal present without enzyme | Non-enzymatic hydrolysis or a contaminated NAD+ stock |
| Nicotinamide spike | Rate does not fall | Assay insensitive to feedback, or enzyme not NAD+-dependent |
| Orthogonal readout | Effect disappears | Artifact of the detection peptide or label |
The stock is itself a variable. NAD+ solutions are subject to degradation that releases nicotinamide, so a stock that has aged can raise the baseline of a nicotinamide-based readout and bring a built-in inhibitor into the reaction. Stock handling is discussed in the sibling article on NAD+ stability and QC, and the general rules in how long reconstituted peptides last.
Setting the NAD+ concentration
The working concentration is a design decision that should come from the enzyme's behavior, not from a convention. Concentration arithmetic is simple: concentration equals mass divided by molar mass divided by volume, with molar mass of about 663 g/mol from the formula C21H27N7O14P2 on the NAD+ product page. The reconstitution calculator will do the conversion for a stock; the experimenter then decides the dilution into the reaction. The reasoning for the choice is as follows.
- Run a titration to estimate the apparent Km for NAD+ with the substrate and buffer in use.
- For a screen where inhibitors are sought, working near the apparent Km keeps the assay sensitive to competitive effects; far above it, competitive effects are masked.
- For a screen for an effect that raises activity, working below saturation leaves room for a rise to be seen.
- Check that consumption stays small over the assay time, so that the NAD+ concentration is approximately constant.
Whichever choice is made, record the value and the stock lot. A result reported with no NAD+ concentration cannot be compared with another laboratory's result.
Buffers, additives and the matrix
Sirtuin assays are run in a variety of buffers, and the buffer can affect the cofactor. A study of nicotinamide cofactor stability found faster degradation of the reduced form in phosphate buffer than in an alternative (Rover et al., 1998). It examined NADH, not NAD+, but it is a reminder to state the buffer and to test whether a change of buffer changes the baseline. Reducing agents, detergents and carrier proteins are additional variables: each can alter the enzyme or interact with a peptide substrate, and each should be in the controls as well as in the samples. If the matrix is a cell lysate, the other NAD-consuming enzymes are present, and a parallel reaction without the sirtuin substrate shows how much NAD+ is lost to them.
Reporting
A reproducible methods paragraph names the enzyme source and construct, the acylated substrate, the NAD+ lot and concentration, the buffer, temperature, time, the readout and the controls above. It states how the NAD+ stock was prepared and verified, and it keeps the raw chromatograms or plate data. Where the study is a comparison, the same lot and stock should be used across arms. For the identity and documentation questions at the receiving stage, see how to read a COA and the COA library; for the broader catalog, the shop. Related enzyme-level background is in NAD+ research applications.
Frequently asked questions
Is NAD+ an activator of sirtuins?
In a purified system it is a co-substrate: more NAD+ raises the rate toward saturation, as for any substrate. That is not allosteric activation, and the reaction consumes NAD+.
What are the products of a sirtuin reaction?
The deacylated protein, nicotinamide and an ADP-ribose product that carries the acyl group, as described in the biochemical reviews.
Why is nicotinamide a problem in sirtuin assays?
It is released by the reaction and was proposed as a negative regulator of yeast Sir2 and human SIRT1 (Bitterman et al., 2002). Accumulation or a contaminated NAD+ stock can lower the apparent activity.
Are resveratrol and SRT1720 direct SIRT1 activators?
One study concluded that they are not, reporting that they interact with fluorophore-containing peptide substrates (Pacholec et al., 2010). Orthogonal readouts are advisable.
Which NAD+ concentration should I use?
Titrate NAD+ with the substrate and buffer in use, estimate the apparent affinity, and choose a concentration suited to the question: near Km for inhibition studies, below saturation for studies looking for a rise in activity.
What controls are essential?
No-NAD+, no-enzyme, a nicotinamide spike, an NAD+ titration, a time course inside the linear range, and an HPLC check of the NAD+ stock.
Do other enzymes compete for NAD+?
Yes. PARPs and NADases such as CD38 also consume it. In lysates, run a parallel reaction without the sirtuin substrate to see how much NAD+ is lost to other enzymes.
Does buffer choice matter?
It can. A cofactor-stability study found faster loss of NADH in phosphate buffer. State the buffer and test whether changing it shifts the baseline.
How do I prepare the NAD+ stock?
Compute concentration as mass divided by molar mass divided by volume, using about 663 g/mol, dissolve in the chosen buffer, divide into single-use portions and record the lot.
How is NAD+ measured in samples?
Reverse-phase HPLC with UV detection and targeted LC-MS methods have both been published for NAD+ and related metabolites.
Research-use statement
All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.
Related reading: NAD+ and Aging Biology: Evidence and Limits, NAD+ Biosynthesis: Precursor Routes and Assay Design, NAD+ and Mitochondria: Respirometry and Mitonuclear Readouts.
References
- Imai Si, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800. doi:10.1038/35001622
- Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. U.S.A.. 2000;97(11):5807-5811. doi:10.1073/pnas.110148297
- Sauve AA, Wolberger C, Schramm VL, Boeke JD. The Biochemistry of Sirtuins. Annu. Rev. Biochem.. 2006;75(1):435-465. doi:10.1146/annurev.biochem.74.082803.133500
- Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1. Journal of Biological Chemistry. 2002;277(47):45099-45107. doi:10.1074/jbc.M205670200
- Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. Journal of Biological Chemistry. 2010;285(11):8340-8351. doi:10.1074/jbc.M109.088682
- Camacho-Pereira J, Tarragó MG, Chini CC, Nin V, Escande C, Warner GM, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;23(6):1127-1139. doi:10.1016/j.cmet.2016.05.006
- Trammell SA, Brenner C. TARGETED, LCMS-BASED METABOLOMICS FOR QUANTITATIVE MEASUREMENT OF NAD + METABOLITES. Comput Struct Biotechnol J. 2013;4(5):e201301012. doi:10.5936/csbj.201301012
- Yoshino J, Imai Si. Accurate Measurement of Nicotinamide Adenine Dinucleotide (NAD+) with High-Performance Liquid Chromatography. Methods in Molecular Biology. 2013;:203-215. doi:10.1007/978-1-62703-637-5_14
- Rover L, Fernandes JC, Neto GdO, Kubota LT, Katekawa E, Serrano SH. Study of NADH Stability Using Ultraviolet–Visible Spectrophotometric Analysis and Factorial Design. Analytical Biochemistry. 1998;260(1):50-55. doi:10.1006/abio.1998.2656
